Dermata Non Current Liabilities Total from 2010 to 2025
| DRMAW Stock | USD 0.02 0.01 31.43% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 1.2 B | Current Value 1.2 B | Quarterly Volatility 432.4 M |
Check Dermata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermata Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 237.1 K, Depreciation And Amortization of 9.7 M or Interest Expense of 111.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0014. Dermata financial statements analysis is a perfect complement when working with Dermata Therapeutics Valuation or Volatility modules.
Dermata | Non Current Liabilities Total |
Latest Dermata Therapeutics' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Dermata Therapeutics Warrant over the last few years. It is Dermata Therapeutics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermata Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Dermata Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 197,224,183 | |
| Geometric Mean | 2,523,574 | |
| Coefficient Of Variation | 219.23 | |
| Mean Deviation | 319,215,075 | |
| Median | 553,191 | |
| Standard Deviation | 432,365,666 | |
| Sample Variance | 186940.1T | |
| Range | 1.2B | |
| R-Value | 0.68 | |
| Mean Square Error | 108464.1T | |
| R-Squared | 0.46 | |
| Significance | 0 | |
| Slope | 61,491,345 | |
| Total Sum of Squares | 2804101T |
Dermata Non Current Liabilities Total History
About Dermata Therapeutics Financial Statements
Dermata Therapeutics investors use historical fundamental indicators, such as Dermata Therapeutics' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dermata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 1.2 B | 1.2 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.